Clinical Trials
9 trialsNCT07594106 2026-05-18
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Regeneron Pharmaceuticals
Phase 1/2 Not yet recruiting
NCT07188896 2026-05-01
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06413680 2026-04-28
BrILliance
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT06699602 2026-03-04
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07223541 2026-03-02
LAG-BOOST
University of Oklahoma
Phase 2 Recruiting
NCT06052852 2025-11-17
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase 1 Terminated
NCT03972657 2025-11-06
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT03294083 2022-10-27
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
SillaJen, Inc.
Phase 1/2 Active not recruiting